CAMBRIDGE, Mass.--(BUSINESS WIRE)--Foundation Medicine, Inc. (NASDAQ:FMI) today announced that members of the company's management team will present at the following upcoming investor conferences:
- Michael J. Pellini, M.D., president and chief executive officer, will present at the Goldman Sachs SMID Cap Growth Conference on Thursday, November 20, 2014 at 2:20 p.m. E.T. in New York, NY.
- Jason Ryan, Senior Vice President, Finance, will present at the Canaccord Genuity Medical Technology & Diagnostics Forum on Thursday, November 20, 2014 at 10:30 a.m. E.T. in New York, NY.
Live, listen-only webcasts of the presentations may be accessed by visiting the investors section of the company’s website at investors.foundationmedicine.com. A replay of each webcast will be available shortly after the conclusion of the presentation and will be archived on the company's website for two weeks following each presentation.
About Foundation Medicine
Foundation Medicine (NASDAQ: FMI) is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient’s unique cancer. The company’s clinical assays, FoundationOne for solid tumors and FoundationOne Heme for hematologic malignancies, sarcomas and pediatric cancers, provide a fully informative genomic profile to identify the molecular alterations in a patient’s cancer and match them with relevant targeted therapies and clinical trials. Foundation Medicine’s molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer. For more information, please visit http://www.FoundationMedicine.com or follow Foundation Medicine on Twitter (@FoundationATCG).
Foundation Medicine® and FoundationOne® are registered trademarks of Foundation Medicine, Inc.
